Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Apsonic
- Development stage
- Unknown
- Lead developer
- Genspec Lifesciences
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Oral
01
Overview
**Apsonic** is an oral fixed-dose analgesic and anti-inflammatory combination developed by Genspec Lifesciences. It contains aceclofenac, a nonsteroidal anti-inflammatory drug that inhibits cyclooxygenase-mediated prostaglandin synthesis; paracetamol, an analgesic and antipyretic; and serratiopeptidase, a proteolytic enzyme used to help reduce inflammatory swelling. It is intended for the management of pain and inflammation.
- Brand names
- Apsonic
- Other names
- aceclofenac + paracetamol + serratiopeptidase
02
Targets
PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)
Beyond the preview
Go deeper on Apsonic.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Apsonic.